|
|
||||||||
Receptor Expression on Normal and Chronic Myeloid Leukemia CD34+ Cells1


*
Leukemia Research Fund Cellular Development Unit, University of Manchester Institute of Science and Technology (UMIST), Manchester, United Kingdom;
Department of Clinical Hematology, Manchester Royal Infirmary, Manchester, United Kingdom;
The Beatson Institute for Cancer Research, Glasgow, United Kingdom; and
§
Department of Haematology, Nottingham City Hospital, Nottingham, United Kingdom
We have assessed expression of MIP-1
binding sites on the
surface of CD34+ cells from normal bone marrow (NBM) and
chronic myeloid leukemia (CML) peripheral blood. This study has
highlighted a small subpopulation of CD34+ (15.7 ±
6.2% in NBM and 9 ± 4% in CML), which has specific
macrophage-inflammatory protein-1
(MIP-1
) cell surface binding
sites. Further phenotypic characterization of the receptor-bearing
cells has shown that they do not express the Thy-1 Ag, suggesting that
they are committed progenitor cells rather than CD34+
Thy+ stem cells. However, more than 80% of methanol-fixed
CD34+ cells do bind MIP-1
, suggesting that these cells
may possess a pool of internal receptors, although we were unable to
induce cell surface expression by cytokine stimulation. The percentage
of these CD34+, MIP-1
-R+ cells present in
the CD34 compartment of NBM is significantly higher than in CML,
implicating lack of binding sites as part of the mechanism for the loss
of response to this chemokine seen in CML. Specific Ab to the MIP-1
receptor implicated in HIV infection, CCR5, revealed that very few
CD34+ cells expressed these receptors and that expression
was confined to the CD34+ Thy- progenitor
population. Data presented in this work suggest that active binding
sites for the stem cell growth inhibitor MIP-1
are not
constitutively expressed on the surface of most resting primitive
multipotent cells, and that these cells are not potential targets for
HIV-1 infection through CCR5.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |